Viraday is a combination of three anti-HIV drugs including efavirenz 600 mg, tenofovir 300 mg and emtricitabine 200mg.
A single tablet of Viraday could provide all the medicine required for an HIV infected persons to deal with the viral load so the person need not take three separate medicines.
This treatment is not only less cumbersome but could be taken even when the HIV infected person is taking medicine for tuberculosis which is not the case otherwise.
Cipla on Thursday became the first company to launch the combination drug in India.
This combination is drug was earlier available only in the United States and European countries.
However, the cost of this combination therapy in the US and Europe is Rs 52,800 per month while Cipla has made it available here at just Rs 5200 per month.
The toxicity of this combination drug has been found to be lower than the drugs taken individually.
for more:- http://news.moneycontrol.com/india/news/health/indiasownonceadayaidsdrugaids/indiasownonceadayaidsdrug/22/49/article/246528